The pair of molecules is the same — semaglutide + cagrilintide. What differs is the regulatory framework. CagriSema® is a clinically investigated drug by Novo Nordisk (phase III, REDEFINE program), unregistered, available exclusively within controlled studies under medical supervision. Semaglutide + Cagrilintide 2+2 mg is a Research Use Only reagent in PEN format with analytical documentation (COA, HPLC, MS Q-TOF), intended exclusively for further laboratory research. The RUO reagent is not a substitute for the investigational drug or the registered drug and does not replace medical consultation.
SEMA+CAGRI 2mg+2mg PEN
Semaglutide + Cagrilintide 2+2 mg — a two-component RUO reagent in PEN format: semaglutide (GLP-1 analog) plus cagrilintide (amylin analog), nominally 2 mg of each component, or 4 mg in total; solution parameters according to the batch documentation. Two independent satiety pathways (GLP-1R + amylin receptors) in a single assay; concentration must be confirmed in the batch documentation.
Semaglutide + Cagrilintide 2+2 mg — semaglutide + cagrilintide in PEN format
- SEMA+CAGRI: semaglutide and cagrilintide, two separate molecules.
- Solution in a PEN: nominally 2 mg + 2 mg, or 4 mg total; parameters according to batch documentation.
- Research Use Only reagent, not a medicinal product.
Sema+Cagri – A chemical reagent intended exclusively for laboratory research (Research Use Only). It is not a medicinal product, dietary supplement, or food product. It is not intended for use in humans or animals. Sold exclusively to registered research entities and laboratories.
Throughout the entire past decade, metabolic pharmacology revolved around a single receptor — GLP-1. Semaglutide set the bar, tirzepatide added a second axis (GIP), and the next research question became: what changes when an analogue of amylin — the second satiety hormone, acting through an entirely separate receptor pathway — is added to a GLP-1 agonist?
This is how the concept behind the cagrilintide + semaglutide combination arose: two independent “enough eating” signal channels stimulated simultaneously. In the reference literature, this direction is described in studies on cagrilintide as monotherapy as well as early combination studies, and the REDEFINE registration program (phase III) is being conducted by Novo Nordisk. In the Pro-Body catalog, the same pair of molecules appears in a separate regulatory framework — as a two-component RUO research reagent, one of the weight loss peptides used in metabolic research on obesity.
This variant supplies both molecules in the form of a solution in a PEN containing nominally 2 mg of semaglutide and 2 mg of cagrilintide, or 4 mg in total: SEMA+CAGRI 2 mg / 2 mg PEN with a factory-prepared solution. Volume, concentration, vehicle composition and storage conditions must be established from the specific batch documentation.
This is a technical solution for laboratories working with the incretin-amylin axis in in vitro and in vivo models — not a medicinal form, not a therapeutic analogue for administration to humans. The single-component line remains available in parallel: SEMA G — Semaglutide alone as a GLP-1 monoagonist, serving as a reference point for a single satiety signal axis.
Incretins and amylin — two pathways of the same satiety
To understand why two molecules are combined, one must see that the body signals satiety through more than one channel. The incretin axis (GLP-1, GIP) and amylin are two separate systems that evolutionarily contribute to the same effect — the “enough” message — yet they do so through different receptors and different neuron populations.
- GLP-1 (glucagon-like peptide 1) is secreted in the intestine after a meal. It acts on pancreatic β cells (glucose-dependent insulin secretion), on α cells (inhibition of glucagon), and centrally — in the arcuate nucleus of the hypothalamus it modulates appetite and slows gastric emptying. This is the channel on which semaglutide relies.
- Amylin is in turn a hormone secreted by the same pancreatic β cells together with insulin, in response to a meal. It signals satiety mainly through the brainstem (area postrema, nucleus of the solitary tract) via amylin receptors — complexes of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMP). This is a different pathway than GLP-1, which makes amylin a complementary, not redundant, regulator of food intake. Cagrilintide is a long-acting, acylated analogue of amylin.
The research hypothesis behind the combination is simple in its premise: if we stimulate two independent satiety pathways simultaneously, the effect on markers of food intake and body mass in models may be greater than for each pathway separately. Early clinical data on the cagrilintide + semaglutide combination as well as the REDEFINE program test precisely this premise — in cohorts of patients, under medical supervision, with investigational drugs, and not with an RUO reagent.
What is Semaglutide + Cagrilintide 2+2 mg — two active components
Semaglutide + Cagrilintide 2+2 mg is a combination of two separate peptides in one PEN, nominally 2 mg of semaglutide and 2 mg of cagrilintide, or 4 mg in total. The actual content and identity of both components must be confirmed in the specific batch COA. Below is a characterization of each component separately.
Component 1 — semaglutide (GLP-1 analogue)
Semaglutide is a GLP-1 receptor (GLP-1R) monoagonist — a stabilized analogue of the endogenous glucagon-like peptide 1. The molecule comprises 31 amino acids, with a molecular mass of about 4113 Da. Relative to human GLP-1, structural modifications were introduced stabilizing the peptide against enzymatic degradation, as well as C18 fatty acid acylation, which enables reversible binding to serum albumin — albumin acts as a reservoir, thanks to which the serum half-life is about 7 days (weekly regimen in the clinical protocols of Ozempic® and Wegovy®).
A full breakdown of the GLP-1R receptor cascade can be found in the description of SEMA G — Semaglutide alone; here we treat this component as one of the two axes of the combination.
| Parameter | Value |
|---|---|
| Common name | Semaglutide (semaglutide) |
| Pharmacological class | GLP-1 receptor (GLP-1R) monoagonist |
| CAS number | 910463-68-2 |
| Molecular formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular mass | ~4113.58 g/mol |
| Number of amino acids | 31 |
| Structural modifications | C18 fatty acid acylation, reversible binding to albumin |
| Serum half-life | ~7 days (weekly regimen in the clinical protocols of Ozempic®/Wegovy®) |
| Content per PEN | Nominally 2 mg of this component; 4 mg total per PEN. Confirm in the batch COA. |
| HPLC purity | ≥98% |
| Identity confirmation | Q-TOF mass spectrometry (MS) |
Component 2 — cagrilintide (amylin analogue)
Cagrilintide is a long-acting, acylated amylin analogue — a human hormone secreted by pancreatic β cells together with insulin. Class: amylin receptor agonist (AMY1–3, complexes of the calcitonin receptor CTR with RAMP proteins) as well as the calcitonin receptor. Acylation enables reversible binding to albumin, which prolongs the duration of action and in the clinical protocols of the investigational drug translates into a weekly regimen — analogously to the retention mechanism described for semaglutide.
The mechanism reported in the literature: enhancement of satiety signaling in the brainstem (complementarily to GLP-1, but through a separate receptor), slowing of gastric emptying, and inhibition of postprandial glucagon secretion.
| Parameter | Value |
|---|---|
| Common name | Cagrilintide (cagrilintide) |
| Pharmacological class | Long-acting amylin analogue; agonist of amylin receptors (AMY1–3) and the calcitonin receptor |
| CAS number | 1415456-99-3 (to be verified in the batch COA) |
| Molecule origin | Acylated analogue of human amylin |
| Structural modifications | Fatty acid acylation, reversible binding to albumin (prolonged action) |
| Action profile | Long-acting (weekly regimen in the clinical protocols of the investigational drug) |
| Content per PEN | Nominally 2 mg of this component; 4 mg total per PEN. Confirm in the batch COA. |
| HPLC purity | ≥98% |
| Identity confirmation | Q-TOF mass spectrometry (MS) |
Two-component mechanism — GLP-1R plus amylin receptors
The action of the combination is based on the simultaneous stimulation of two independent satiety signaling pathways. This distinguishes Semaglutide + Cagrilintide from a pure GLP-1 monoagonist and from a GLP-1/GIP dual agonist — here the second axis is not another incretin receptor, but the amylin system.
The GLP-1 axis (semaglutide). Activation of GLP-1R — a G protein-coupled receptor — raises intracellular cAMP and triggers PKA kinase-dependent pathways. In pancreatic β cells this potentiates glucose-dependent insulin secretion (a molecular “fuse” — the signal is amplified only at elevated glucose), in α cells it inhibits postprandial glucagon, and centrally, in the arcuate nucleus of the hypothalamus, it modulates appetite (activation of POMC neurons) and slows gastric emptying. In a working analogy: semaglutide prolongs the “enough eating” signal — like a button held down longer.
The amylin axis (cagrilintide). Activation of amylin receptors in the brainstem (area postrema, nucleus of the solitary tract) signals satiety through a different receptor and a different neuron population than GLP-1. It adds the slowing of gastric emptying and the inhibition of glucagon secretion. In the analogy: it is the second, independent “enough eating” button — pressed in parallel with the first.
Complementarity, not redundancy. Because both pathways converge on a common effect (limitation of food intake, control of postprandial glycemia), yet start from different receptors, the research hypothesis assumes an additive or synergistic effect on markers of body mass and composition in models. Early studies of the cagrilintide + semaglutide combination (Enebo et al. 2021) reported in humans a profile supporting further development of this pair, and the phase III REDEFINE program tests endpoints of body mass reduction in obesity and type 2 diabetes cohorts — with investigational drugs, under medical supervision.
In this context it was reported that body mass reduction for the studied combination exceeded the result of semaglutide alone — which constitutes a substantive justification for research work on the GLP-1 + amylin pair.
IMPORTANT DISTINCTION
“Body mass reduction”, “satiety” and “glycemic control” in the context of this description refer exclusively to endpoints reported in clinical studies on semaglutide (Ozempic®, Wegovy®) and on the studied cagrilintide + semaglutide combination (CagriSema®, REDEFINE program). This does not imply a guarantee of effect for anyone working with the RUO reagent, nor a suggestion that Semaglutide + Cagrilintide 2+2 mg could serve as a “weight-loss drug”, an “Ozempic® substitute” or a “homemade CagriSema®”. The reagent remains a molecular tool for laboratory research.
PEN variant (RUO) vs pharmaceutical drug and the investigational CagriSema®
| Feature | Semaglutide + Cagrilintide 2+2 mg (RUO, PEN) | Ozempic® / Wegovy® (drug) | CagriSema® (investigational drug) |
|---|---|---|---|
| Regulatory status | Research reagent (Research Use Only) | Registered drug (EMA, FDA) | In registration studies (phase III) — unregistered |
| Active substances | Semaglutide + cagrilintide | Semaglutide | Semaglutide + cagrilintide |
| Form | Solution in a PEN, 2 mg + 2 mg (4 mg total) | Ready-made solution in a pen | Clinical trial material |
| Manufacturer / sponsor | Pro-Body | Novo Nordisk | Novo Nordisk |
| Documentation | COA per batch, HPLC ≥98%, MS Q-TOF | Full EMA/FDA registration documentation, SmPC | Clinical trial documentation (phase III, ongoing) |
| Intended purpose | Laboratory research | Type 2 diabetes / obesity | Clinical studies (obesity, type 2 diabetes) |
| Sale | Trade in chemical reagents | Prescription only | Exclusively within clinical trials |
| Supervision | No medical supervision | Attending physician, pharmacovigilance | Study protocol, bioethics committee |
| Label | „For research use only. Not for human use” | Full drug leaflet | Clinical trial material |
Three separate regulatory frameworks apply to the same pair of molecules. The Novo Nordisk pen (Ozempic®/Wegovy®) is a registered medicinal product with a patient leaflet and EMA pharmacovigilance supervision. CagriSema® is a clinically investigated combination — not yet registered, available exclusively within controlled studies. The PEN in the Pro-Body catalog is a chemical reagent with analytical documentation (COA, HPLC, MS Q-TOF), intended exclusively for further laboratory research.
The identity of the molecules does not abolish the distinction between these frameworks — the fact that the same pair is being clinically investigated does not make the RUO reagent a drug or its substitute.
Applications in scientific research
Semaglutide + Cagrilintide 2+2 mg as a two-component RUO reagent finds application where the subject of study is the interaction of the GLP-1 axis with the amylin axis. The PEN contains a solution with parameters specified in the batch documentation. Experimental design must account for its actual concentration, vehicle and fixed proportion of the two components.
Pharmacology of the GLP-1 + amylin combination. Analyses of receptor activity for both pathways in parallel, profiling of the selectivity of GLP-1R and amylin receptors (CTR/RAMP), EC50 measurements in cell cultures with cAMP reporters. Working dilutions must be planned using the concentration specified in the batch documentation; dilution does not change the proportion of the two components.
Animal models of obesity and insulin resistance. DIO mice, ob/ob and db/db models, Zucker rats. Endpoints: body mass, composition (DEXA, NMR), food intake, OGTT/ITT, HOMA-IR, lipid profile. The combination functions as a tool for studying the additive effect relative to a GLP-1 monoagonist.
Comparative studies of central satiety signaling. Activation of POMC neurons in the arcuate nucleus (GLP-1 axis) vs activation of the brainstem (area postrema, amylin axis) — mapping which pathway is responsible for which component of the effect on food intake in behavioral models.
Structure–activity relationship analyses. Semaglutide + Cagrilintide (GLP-1 + amylin) as a reference point against a GLP-1 monoagonist and against the GLP-1/GIP dual agonist that is Tirzepatide 5 mg, in work on the architecture of multi-target metabolic analogues — accounting for the PEN format and the solution parameters specified in the batch documentation.
Summary
Semaglutide + Cagrilintide 2+2 mg PEN is a two-component reagent supplied as a solution, combining the GLP-1 axis (semaglutide) and the amylin axis (cagrilintide). It nominally contains 2 mg of each component, or 4 mg in total. Concentration, volume and storage conditions must be checked in the batch documentation. The pair of molecules is identical with the clinically investigated combination CagriSema® (Novo Nordisk, phase III, REDEFINE program), yet the RUO reagent functions in a separate regulatory framework: it is not a registered drug, an investigational drug, or their substitute. Check availability in the store and plan laboratory work according to the batch documentation and experimental design.
Bibliography
- Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. PubMed
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. PubMed
- Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. PubMed
- Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. PubMed
- Frías JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, et al. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. PubMed
- Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD (2015). Amylin: Pharmacology, Physiology, and Clinical Potential. PubMed
Two-component chemical reagent Research Use Only. Semaglutide + Cagrilintide 2+2 mg in the Pro-Body catalog is not a medicinal product, dietary supplement, or food product. It is not intended for administration to humans or animals outside a controlled experimental environment. This reagent (RUO) must not be confused with the semaglutide drugs registered by Novo Nordisk (Ozempic®, Wegovy®, Rybelsus®) or with the clinically investigated combination CagriSema® (phase III, REDEFINE program — unregistered).
The active substances are the same (semaglutide, cagrilintide), yet the RUO reagent, the registered drug, and the investigational drug originate from three separate regulatory frameworks with different documentation and intended purposes. These drugs are available exclusively on prescription or within clinical trials and require medical supervision — the RUO reagent does not replace them and does not replace medical consultation.
The information in the description is educational and scientific in nature and refers to results reported in the literature — it does not constitute medical advice or instructions for administration.
FAQ
Because these are two independent satiety signaling systems. GLP-1 acts, among others, centrally through POMC neurons in the arcuate nucleus, amylin — through receptors in the brainstem (area postrema). The research hypothesis assumes that simultaneous stimulation of both pathways yields an additive or synergistic effect on markers of food intake and body mass in models — greater than for each pathway separately. Early clinical data on the combination supported further development of this pair.
The GLP-1 axis (semaglutide) signals satiety mainly through the hypothalamus (arcuate nucleus, POMC neurons) and adds glucose-dependent insulin secretion as well as inhibition of glucagon in the pancreas. The amylin axis (cagrilintide) signals satiety through the brainstem, via amylin receptors that are complexes of the calcitonin receptor (CTR) with RAMP proteins. Different receptors, different neuron populations, a common end effect — which is why we speak of complementarity, not redundancy.
This card describes the PEN variant containing a solution with nominally 2 mg of semaglutide and 2 mg of cagrilintide, or 4 mg in total. It is not a vial of lyophilisate for reconstitution. Solution volume, concentration and vehicle composition must be checked in the specific batch documentation. The PEN format does not imply authorisation for human use.
No. This variant is supplied as a solution in a PEN, not as lyophilisate for dissolution. Preparation for an experiment must follow the batch documentation and approved laboratory protocol. Working parameters and the number of withdrawals must not be assumed without concentration and volume data.
Transport, storage, handling after first opening and stability of both components must follow the specific batch documentation. Recommendations for dry lyophilisate must not be transferred to the PEN. Do not state a universal temperature, suitability for freezing or shelf life without manufacturer data.
Semaglutide is not prohibited and is included in WADA’s Monitoring Program. As of October 2026, cagrilintide has no marketing authorisation in any country, so it falls under class S0 of the Prohibited List (non-approved substances) and is prohibited at all times. Authorisation of a medicine containing cagrilintide would change this status. Registered athletes (ADAMS) should check the current list and the Monitoring Program before any decision.
-
Michal
Polski
Product review
Wszystko ok. Polecam :)